Trial · NCT02130882

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882, Phase 2, Phase 3, Unknown, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2022-02-08

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome. Trials, record NCT02130882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02130882

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
NCT number: NCT02130882
Status: Unknown
Phases: Phase 2, Phase 3
Enrollment: 20 participants, actual
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo
First posted: 2014-05-06
Last updated: 2022-02-08
Results first posted: 2022-02-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia	3 months	50% reduction in peripheral blood eosinophilia on stable HES background therapy at 12 weeks post-initiation of study drug
Secondary	Percent Reduction in Eosinophil Count	3 months	Percent reduction in peripheral blood eosinophilia at 12 weeks post-treatment

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia	3 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percent Reduction in Eosinophil Count	3 months		Percent reduction in eosinophil count	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia	Drug	9		Participants
Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia	Placebo	3		Participants
Percent Reduction in Eosinophil Count	Drug	100	Full Range 49 to 100	Percent reduction in eosinophil count
Percent Reduction in Eosinophil Count	Placebo	14	Full Range -15 to 89	Percent reduction in eosinophil count

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Drug	10
Overall Study	STARTED	Placebo	10
Overall Study	COMPLETED	Drug	10
Overall Study	COMPLETED	Placebo	9
Overall Study	NOT COMPLETED	Drug	0
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Lymphocytopenia	Blood and lymphatic system disorders	Drug	6	10
other	Lymphocytopenia	Blood and lymphatic system disorders	Placebo	1	10
other	Headache	Nervous system disorders	Drug	7	10
other	Headache	Nervous system disorders	Placebo	4	10
other	Elevated serum lactic dehydrogenase	Investigations	Drug	5	10
other	Elevated serum lactic dehydrogenase	Investigations	Placebo	1	10
other	Anemia	Blood and lymphatic system disorders	Drug	7	10
other	Anemia	Blood and lymphatic system disorders	Placebo	4	10
other	Fatigue	General disorders	Drug	5	10
other	Fatigue	General disorders	Placebo	4	10

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Drug	0	10
Total, all-cause mortality	Placebo	0	10
Total, other adverse events	Drug	10	10
Total, other adverse events	Placebo	10	10
Total, serious adverse events	Drug	0	10
Total, serious adverse events	Placebo	1	10

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20513525	BACKGROUND	PubMed
21762978	BACKGROUND	PubMed
30943337	BACKGROUND	PubMed
35283330	DERIVED	PubMed
40120806	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Drug vs Placebo: Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia	Trial comparisons
Drug vs Placebo: deaths from any cause	Trial comparisons
Drug vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02130882

GET https://conductscience.org/api/trials/v1/NCT02130882/events?page=2

API reference For AI assistants